Journal of the American Academy of Dermatology · 2017
New therapies for atopic dermatitis: Additional treatment classes.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vakharia Paras P, Silverberg Jonathan I
Аннотация
BACKGROUND: A wide array of miscellaneous agents is being studied for the treatment of atopic dermatitis (AD), including targeted topical, oral systemic, and biologic agents.
OBJECTIVE: To review the known efficacy and safety to date for such agents being studied for the treatment of AD.
METHODS: A nonsystematic review of the literature was performed. PubMed and ClinicalTrials.gov were searched for studies assessing agents not described previously for the treatment of AD. Randomized controlled trials were primarily sought, but other study types were also included if they contained pertinent data. Agents are presented by mechanism of action, with analysis of mechanism of action and data regarding efficacy and safety in patients with AD.
RESULTS: Data regarding the following agents are presented: omiganan (an antimicrobial peptide), tapinarof (a nonsteroidal anti-inflammatory agent), PR022 (hypochlorous acid), asimadoline (a κ-opioid agonist), DS107 (dihomo-γ-linolenic acid), ZPL-389 (a histamine H4 receptor antagonist), secukinumab (an interleukin 17A inhibitor), and fezakinumab (interleukin 22 inhibitor).
LIMITATIONS: Limited clinical data exist for many of the described agents.
CONCLUSIONS: As recent research has improved our understanding of AD pathogenesis, various agents with unique mechanisms of action have been studied for the treatment of AD. Many of these hold great therapeutic promise for AD, and continued research and development is warranted.
OBJECTIVE: To review the known efficacy and safety to date for such agents being studied for the treatment of AD.
METHODS: A nonsystematic review of the literature was performed. PubMed and ClinicalTrials.gov were searched for studies assessing agents not described previously for the treatment of AD. Randomized controlled trials were primarily sought, but other study types were also included if they contained pertinent data. Agents are presented by mechanism of action, with analysis of mechanism of action and data regarding efficacy and safety in patients with AD.
RESULTS: Data regarding the following agents are presented: omiganan (an antimicrobial peptide), tapinarof (a nonsteroidal anti-inflammatory agent), PR022 (hypochlorous acid), asimadoline (a κ-opioid agonist), DS107 (dihomo-γ-linolenic acid), ZPL-389 (a histamine H4 receptor antagonist), secukinumab (an interleukin 17A inhibitor), and fezakinumab (interleukin 22 inhibitor).
LIMITATIONS: Limited clinical data exist for many of the described agents.
CONCLUSIONS: As recent research has improved our understanding of AD pathogenesis, various agents with unique mechanisms of action have been studied for the treatment of AD. Many of these hold great therapeutic promise for AD, and continued research and development is warranted.
Предметные рубрики MeSH
AcetamidesAdministration, TopicalAdultAnti-Infective AgentsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntimicrobial Cationic PeptidesBiological ProductsClinical Trials, Phase II as TopicDermatitis, AtopicDouble-Blind MethodFemaleHumansImmunosuppressive AgentsMalePrognosisPyrrolidinesRandomized Controlled Trials as TopicTreatment Outcome